<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I:  Protective T Cell Vaccine for SARS CoV-2  (COVID-19)</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>01/01/2022</AwardEffectiveDate>
<AwardExpirationDate>12/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a fundamentally different next-generation SARS CoV-2 vaccine that addresses current gaps in efficacy, safety, and national and global distribution of  vaccines. The rapid global emergence of the highly infectious delta variant underscores the importance of T cell immunity, increasingly recognized as critical to eliciting effective and long-term immunity to SARS CoV-2. An innovative DNA vaccine, delivered as a patient-friendly intranasal spray that does not require refrigeration, will improve public health.  &lt;br/&gt;&lt;br/&gt;This Small Business Technology Transfer (STTR) Phase I project advances a multivalent SARS CoV-2 T cell vaccine by intranasal/pulmonary administration of calcium phosphate nanoparticle-formulated plasmids.  Proteins comprising the SARS CoV-2 ORFeome will be cloned in proprietary plasmids (Aim 1) screened by in vitro challenge with PBMC from recovered donors (Aim 2) and safety/immunogenicity/challenge in vivo in hACE2 mice. The outcome of Phase I will be identification novel ORFs that elicit T cell responses in vivo and that in combination partially protective (50% survival at 14 days post infection) against challenge with SARS CoV-2.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>12/21/2021</MinAmdLetterDate>
<MaxAmdLetterDate>12/21/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2131876</AwardID>
<Investigator>
<FirstName>Lorraine</FirstName>
<LastName>Keller</LastName>
<PI_MID_INIT>H</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Lorraine H Keller</PI_FULL_NAME>
<EmailAddress>lkeller@mbftherapeutics.com</EmailAddress>
<PI_PHON>2152056084</PI_PHON>
<NSF_ID>000827320</NSF_ID>
<StartDate>12/21/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>MBF THERAPEUTICS, INC.</Name>
<CityName>AMBLER</CityName>
<ZipCode>190021828</ZipCode>
<PhoneNumber>2156203699</PhoneNumber>
<StreetAddress>640 WOODBROOK DR</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Pennsylvania</StateName>
<StateCode>PA</StateCode>
<CONGRESSDISTRICT>01</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>PA01</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>829416853</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>MBF THERAPEUTICS, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[MBF THERAPEUTICS, INC.]]></Name>
<CityName>warminster</CityName>
<StateCode>PA</StateCode>
<ZipCode>189741450</ZipCode>
<StreetAddress><![CDATA[46 steamwhistle dr]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Pennsylvania</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>01</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>PA01</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>1982</Code>
<Text>BIOLOGICAL CHEMISTRY</Text>
</ProgramReference>
<Appropriation>
<Code/>
<Name/>
<APP_SYMB_ID/>
</Appropriation>
<Fund>
<Code>01002223DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<FUND_OBLG>2022~256000</FUND_OBLG>
</Award>
</rootTag>
